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ABSTRACT 
Prodrugs or predrugs are inactive molecules which become active after 
in vivo conversion to release the active parent drug. The prodrug’s 
cleavage can be catalyzed by metabolic enzymes or can occur by 
chemical means without the involvement of enzymes. Prodrugs are 
designed to improve undesirable physicochemical and pharmacokinetic 
properties of their parent drugs. Non-steroidal anti-inflammatory 
(NSAIDs) drugs are among the most commonly used drugs for 
treatment of pain, inflammation and fever. Despite their frequent use, 
these agents suffer from gastrointestinal side effects that limit their use 
for those patients with gastrointestinal conditions. This mini review 
discusses the design, synthesis and pharmacological effects of 
prodrugs and codrugs of the non-steroidal anti-inflammatory  
(NSAIDs) Diclofenac sodium or potassium. It argues that the prodrug approach has the 
potential to eliminate Diclofenac associated gastrointestinal complications, increases its 
bioavailability and masks its bitter taste. 
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Prodrugs are molecules which are converted in vivo to their parent active drugs by enzymatic 
or chemical transformation to give theraputic effect.
[1-2]
 Prodrugs have many advantages over 
their parent drugs, they are designed to improve the physicochemical and pharmacokinetic 
properties of their parent active drugs and hence to an improvement in their  oral absorption, 
aqueous solubility and bioavailability and a reduction in their toxicity and/or bitter 
sensation.
[2-3]
 
 
Historically, prodrugs of chloramphenicol were the first to be synthesized by Davis 
Company. The company’s goal was to make more water soluble derivatives such as 
chloramphenicol sodium succinate, and bitterless derivatives such as chloramphenicol 
palmitate.
[4-5]
 
 
Prodrugs are classified into two classes: (1) carrier linked prodrugs, in which  the active drug 
is linked covalently to a nontoxic linker; the cleavage of the linkage in this class occurs by 
uncatalyzed or enzyme catalyzed chemical reaction to provide the active parent drug. The 
non-toxic linker is then excreted out the body.
[6] 
This class is divided into three subclasses: (i) 
bipartite which consists of one linker; (ii) tripartite, which has a spacer connecting the drug 
and linker and (iii) mutual prodrugs, which consist of two drugs attached together. (2) 
bioprecursor prodrugs, which themselves do not have any therapeutic effect until they 
undergo in vivo metabolism to metabolites having therapeutic effects.
[7]
 
 
Since 1960, prodrug design has become much more popular which consequently resulted in 
promoting and progressing the drug discovery and development field.
[8]
 Recent statistical 
studies showed that about 10% of all marketed drugs worldwide are prodrugs. In 2008 alone, 
about 33% of all approved small-molecular-weight medications were prodrugs. In 2009, 
about 15% of the 100 highest selling small molecular-weight drugs were prodrugs.
[1, 9]
 
 
Figure 1: Number of publications for prodrugs found in Scifinder.
[1]
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Non-steroidal anti-inflammatory drugs (NSAIDs) are considered as the best treatment for 
conditions associated with pain, fever and inflammation.
[10]
 Several epidemiological reports 
have indicated that non-steroidal anti-inflammatory agents have shown to play a role in 
inhibiting cancerous cells and some of these drugs have even showed positive results in 
human studies.
[11]
 
 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID), which has a strong analgesic 
and anti-inflammatory effect. Tablets and suppositories of Diclofenac are prescribed for 
fever, pain relief and chronic inflammatory diseases such as osteoarthritis.
[12-13]
 
 
Diclofenac like other non-steroidal anti-inflammatory drugs exerts its therapeutic effect by 
blocking prostaglandin synthesis from arachidonic acid, which inhibits the activity of 
cyclooxygenases (COX-1 and COX-20.
[14] 
COX-1 is located in the stomach, kidney, and 
other tissues, while COX-2 is located at inflammation sites.
[15-16]
 
 
Although the NSAIDs are the most used class of drugs throughout the world (in 2009, their 
sale benefit was more than $9 billion),
[17] 
NSAIDs use can cause severe stomach problems 
including hemorrhaging, ulceration, and cardiovascular side effects. These complications 
may cause withdrawal cases in patients under NSAIDs treatment.
[18]
 A study report on ‘Toxic 
and Deadly NSAIDs’, stated that NSAID gastrointestinal side effects on arthritis patients 
resulted in about 107,000 hospitalization cases and about 16,500 deaths per year in the United 
States, alone.
[17] 
 
Classical NSAIDs, such Diclofenac, inhibit COX-1 activity and block the biosynthesis of 
prostaglandins that protect the gastric mucosa, they also cause local irritation by the free 
carboxylic acid contained in their structures. Both factors are the source for the 
gastrointestinal complications resulted from the use of NSAIDs. 
 
It is widely believed that eliminating the gastrointestinal side effects and reducing the toxicity 
associated with the NSAIDs use can be achieved via chemical modifications of the main 
functional groups contained in the NSAID structure.
[19]
 
 
These chemical modifications include: (1) ester and amide prodrug derivatives: ester 
prodrugs are synthesized by reacting the carboxylic group of the NSAID with an alcohol. On 
the other hand, amide prodrugs are made by the reaction of the carboxylic group of the 
NSAID (via an acyl halide) with an amine. The hydrolysis reactions for ester and amide 
www.wjpps.com                                Vol 4, Issue 07, 2015.                                            
            
 
1963 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
prodrugs are generally catalyzed by enzymes, esterases for ester hydrolysis and amidases for 
amide hydrolysis.  (2) Anhydride prodrugs of NSAIDs:  these are synthesized by a reaction of 
the carboxylic group of the NSAID with another carboxylic group. Generally, the anhydride 
linkage is more labile to hydrolysis than the ester and amide linkages, and undergoes 
cleavage to the corresponding carboxylic acid (the NSAID parent drug) in a controlled 
manner.
[20]
 (3) Mutual prodrugs are two active drugs that are linked to each other by a 
covalent bond to furnish a single inactive moiety that is enzymatically or chemically 
converted to the active parent drugs
[21]
 and (4) amino acids and 5- glucosamine conjugate 
prodrugs of NSAIDs. 
 
In 1993, morpholinoalkyl esters of Diclofenac (Figure 2) were synthesized and their 
hydrolysis, in phosphate buffer pH 7.4 and plasma of rats, was evaluated. The prodrugs were 
found to have better absorption than their parent drug and they underwent cleavage in fast 
rates. In addition, the study showed that in vivo irritation of gastrointestinal mucosa of rat was 
significantly lower using these prodrugs compared to that after a single and chronic oral 
administration of Diclofenac (the active parent drug).
[22]
 
 
 
Figure 2: Chemical structure of morpholinoalkyl Diclofenac ester prodrugs. 
 
Tabrizi and coworkers have made several Diclofenac prodrugs by attaching Diclofenac to 
polychloromethylstyrene, polyvinyl chloroacetate and polyethylene glycol through a labile 
ester bond. The group found that polymers are useful as polymeric prodrugs while the 
polyvinyl chloroacetate was evaluated as a good carrier for in vivo release of the drug. The 
hydrolysis of polymer-drug conjugates in cellophane membrane dialysis bags containing 
buffer solutions pH 8 at 37 Cº was studied and the rate of the hydrolysis was determined. 
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However, no sharp results were obtained and further study should be undertaken to draw 
conclusions on the feasibility of using these prodrugs in human.
[23]
 
 
In 1996, several NSAIDs such as Ibuprofen, Naproxen, Diclofenac and Ketorolac were 
reacted with R-(-)-2-amino-1-butanol with the aim of providing the corresponding amide 
prodrugs with better bioavailability and less gastrointestinal side effects. The analgesic 
activity and toxicity of the synthesized prodrugs were investigated and compared to that of 
the corresponding active parent drugs.
[24]
 
 
In 1997, Jilani et al. has synthesized hydroxyethyl esters of Diclofenac and Mefenamic acid 
aiming to provide NSAIDs prodrugs with efficient analgesic activity and lesser 
gastrointestinal side effects than their active parent drugs. Stability study on those prodrugs 
was conducted in 1N HCl, buffer solutions of pH 7.4 and human plasma. The hydrolytic 
degradation rate of the Diclofenac ester in aqueous buffer solutions was very slow with a 
half-life of more than 22 hours, whereas the degradation rate in human plasma was very fast 
with a half-life value of less than 1.2 hours. This indicates that the Diclofenac prodrug is 
quite stable in the stomach conditions and hence it is expected that its gastrointestinal side 
effects will be lesser than that of Diclofenac due to masking the free carboxylic group in 
Diclofenac, which is believed to be responsible in part for these adverse effects.
[25] 
 
In 1999, Mahfouz et al. has conducted ulcerogenicity study, using electron microscopy on 
rat’s stomach; the rats were treated for 4 days with the synthesized NSAIDs ester prodrugs 
before the ulcerogenicity test. The study revealed that the synthesized prodrugs have shown 
lesser irritation to the stomach’s mucosa than their active parent drugs.[26] 
 
In 2000, Bandarage and coworkers synthesized Diclofenac ester prodrugs containing a 
nitrosothiol (S-NO) group aiming to provide NSAIDs with the capability to donate N-O 
group. These prodrugs were orally administered to mice for bioavailability and toxicity 
evaluation. The study demonstrated that those prodrugs released the active parent drug, 
Diclofenac, in a significant amount within 15 minutes and showed an efficient inflammatory 
effect. The S-NO Diclofenac prodrugs illustrated in Figure 3 were shown to be much safer 
than their active parent drug, Diclofenac. In addition, the study demonstrated that rat stomach 
lesions caused by S-NO-diclofenac derivatives were less than lesions caused by the parent 
drug, Diclofenac.
[27]
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Figure 3: Chemical structures of Diclofenac and its S-NO prodrugs. 
 
In 2000, Seung and coworkers have made several alkyl ester prodrugs of Diclofenac, and 
studied their physicochemical properties such as solubility, partition coefficients, pKa and 
stability in aqueous buffered solutions and in human plasma. The permeation study of the 
synthesized prodrugs across hairless mouse skin indicated that the methyl and ethyl prodrug 
derivatives were found to have higher lipid solubility, log P, of 5.5 and 5.1 at pH 7.0, 
respectively, when compared with their parent drug, Diclofenac. In addition, their study 
revealed that the prodrugs showed moderate chemical stability in aqueous solutions at 
different pHs, except strong acidic and basic conditions, and underwent enzyme catalyzed-
hydrolysis to their parent drug in human plasma. Further, the prodrugs demonstrated a higher 
flux across the hairless mouse skin than their parent drug (2.6-fold of their parent drug). The 
prodrugs lag time and solubility were found to be lesser than Diclofenac and their pKa values 
were in the range of 6.9 and 7.2.
[28]
 
 
In 2002, Hirabayashi and coworkers have carried out a study on in vivo disposition at whole 
body, organ and cellular levels of bisphosphonic prodrug of Diclofenac (DIC-BP) (Figure 4) 
upon administration of a dose in the range of 0.32-10 mg/kg. Their study indicated that both 
total body clearance and volume of distribution at steady state were reduced while the plasma 
half-life was prolonged. In addition, the study revealed that more than 50% of DIC-BP was 
transported into osseous tissues when was given in a dose of up to 1mg/kg, however when the 
dose was increased the skeletal distribution was decreased and both hepatic and splenic 
accumulations were increased. This is because bisphosphonates cannot be distributed in 
tissues but they can form a large complex with endogenous metals in plasma and are 
recognized as foreign substances from macrophages and thus being taken by the 
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reticuloendothelial system. In order to optimize the DIC-BP prodrug’s delivery, the dosage 
regimen should be such that the plasma concentration of DIC-BP is maintained at a level 
lower than that required for precipitate complexes, similar to that of other 
bisphosphonates.
[29]
 
 
 
Figure 4: Chemical structure of Diclofenac bisphosphonic prodrug. 
 
In 2004, Dalpiaz and coworkers have studied the in vitro intracellular uptake of Diclofenac 
and its conjugate ascorbic acid (AA-Diclo) (Figure 5) and their affinity for the SVCT2 
transporter. In addition, the AA-Diclo prodrug stability was investigated. The hydrolysis 
study followed a first-order kinetics with a half-life of about 10 hours in plasma and about 3 
hours in the whole blood, suggesting that AA-Diclo prodrug is a potential candidate to 
enhance the short half-life of Diclo in vivo.
[30]
  
 
 
Figure 5: Chemical structure of AA-Diclo prodrug. 
 
In 2004, Khan and coworkers have synthesized a number of glyceride derivatives of 
Diclofenac and have studied their gastrointestinal side effects, anti-inflammatory and 
analgesic activity. In addition, the group has investigated the release of the active parent drug 
from these prodrugs in a wide range of pHs. Their results revealed that the synthesized 
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glyceride prodrugs were found to lack any gastrointestinal side effects and their analgesic and 
anti-inflammatory effects were significantly greater than that of the active parent drug, 
Diclofenac.
[31]
 
 
In 2009, Manon et al. has synthesized a number of Diclofenac-antioxidant mutual prodrugs 
by conjugating Diclofenac with different antioxidants having anti-ulcerogenic activity. The 
study screening revealed that the synthesized mutual prodrugs retained the anti-inflammatory 
activity as Diclofenac however with lesser ulcerogenic side effects.
[32]
 
 
In 2010, Nemmani et al., has designed, synthesized and evaluated new NO-releasing NSAID 
prodrugs such as NO-Aspirin and NO-Diclofenac (Figure 6). NO-Diclofenac showed 
excellent pharmacokinetic, anti-inflammatory properties. In addition, this prodrug showed 
significant NO-releasing properties and protected rats from NSAID-induced gastric damage 
which could be attributable to the beneficial effects of NO released from this prodrug [33]. 
 
 
Figure 6: Chemical structure of NO-Diclofenac prodrug. 
 
In 2011, Diclofenac ester prodrugs 1-3 (Figure 7) were synthesized and their in vitro and in 
vivo pharmacokinetic and pharmacodynamics properties were evaluated. A study which 
conducted after oral administration of ester prodrugs, 1-3 revealed that these compounds have 
a very good analgesic and anti-inflammatory activity with lesser gastrointestinal irritation 
than their active parent drug, Diclofenac, and they underwent a rapid enzymatic hydrolysis to 
their parent drug.
[34, 35]
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Figure 7: Chemical structures of Diclofenac ester prodrugs 1-3. 
 
In 2012, Santos et al. has synthesized 1-(2,6-dichlorophenyl)indolin-2-one, a Diclofenac 
prodrug, and studied its therapeutic activity. The study demonstrated that the new prodrug 
has shown relevant anti-inflammatory properties without gastrointestinal side effects. 
Furthermore, the study showed that the prodrug decreased PGE2 levels, COX-2 expression 
and cellular influx into peritoneal cavity induced by carrageenan treatment. The 
pharmacokinetic studies on the prodrug have shown in vivo enzyme catalyzed 
interconversion of the prodrug to its parent active drug, Diclofenac. Santos et al. has 
concluded based on this study that the synthesized new nonulcerogenic NSAID prodrug is 
useful to treat inflammatory conditions by long-term therapy.
[36]
  
 
In 2012, Ghosh et al. has synthesized four codrugs of Naltrexone and Diclofenac linked 
together via phenolic or alcoholic linker. Transdermal flux, permeability and skin 
concentration of both parent drugs and codrugs were quantified to form a structure 
permeability relationship. The results revealed that all codrugs underwent bioconversion in 
the skin. The extent of the bioconversion was found to be dependent on the structure; phenol 
linked codrugs were less stable compared to the secondary alcohol linked ones. The flux of 
Naltrexone across microneedle treated skin and the skin concentration of Diclofenac were 
higher for the phenol linked codrugs. The polyethylene glycol link enhanced solubility of the 
codrugs, which translated into flux enhancement. Based on the study results, Gosh et al. 
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concluded that polyethylene glycol linked Naltrexone diclofenac codrug is better suited for a 
7 day drug delivery system both in terms of stability and drug delivery.
[37]
 
 
In 2014, Dhurgham et al. has synthesized codrugs of NSAIDs, Indomethacin and Diclofenac, 
linked to the anticancer drug Gemcitabine (Figure 8). The synthesized codrugs showed 
improved drug targeting for Gemcitabine, reduced stomach side effects of NSAIDs by 
masking their carboxylic acid group and increased their oral bioavailability because COX-2 is 
expressed in cancerous cells more than normal tissue, so the mutual prodrug will specifically 
and efficiently target the cancerous cells.
[38]
 
 
 
Figure 8: Diclofenac‒Gemcitabine conjugate 
 
In 2013, Suryawanshi et al. has synthesized five Diclofenac ester prodrugs (Figure 9) by 
reacting the corresponding alcohol with the NSAID drug aiming at reducing the undesired 
side effects, the most important being gastrointestinal (GI) irritation and ulceration, 
associated with the use of NSAIDS. It is widely believed that using the prodrug approach by 
temporary blocking the free carboxylic group present in the NSAIDs till their systemic 
absorption, is the best way to retain the anti-inflammatory effect of the NSAID and eliminate 
all gastrointestinal adverse effects associated with its use. All five Diclofenac ester prodrugs 
were evaluated for anti-inflammatory activity by Carrageenan Induced Rat hand Paw method 
and all of the prodrugs without exception showed quite appreciable anti-inflammatory 
activity.
[39]
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Figure 9: Ester prodrugs of Diclofenac. 
 
Bhosle and coworkers have synthesized prodrugs and codrugs of NSAIDs with glucosamine 
to mask the carboxylic group of the NSAID in order to decrease its gastrointestinal side 
effects. Glucosamine is an amino sugar, used by human body to produce endogenous joint 
molecules like joint lubricants. Glucosamine hydrochloride and sulphate are being used to 
treat arthritis. The synthesized mutual prodrug of Diclofenac coupled with D-glucosamine 
illustrated in Figure 10 demonstrated a reduction in gastrointestinal irritation and an increase 
in the analgesic and anti-inflammatory effects. In addition, it has demonstrated a quite fair 
anti-arthritic activity.
[40]
 
 
 
Figure 10: Diclofenac D-glucosamine prodrug. 
 
In 2014, Hasan et al. has synthesized eight Diclofenac-Chalcone mutual prodrugs aiming to 
provide anti-inflammatory agents with enhanced anti-inflammatory activity and less 
ulcerogenic adverse effects than their parent drugs. The mutual prodrugs were synthesized by 
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conjugation of Diclofenac with Chalcone derivatives by the Claisen–Schmidt condensation of 
acetophenone or p-hydroxy acetophenone with benzaldehyde or appropriately substituted 
benzaldehyde in the presence of a catalyst. The anti-inflammatory activity of the synthesized 
fluorinated Chalcone derivative was performed using the cotton pellet-induced granuloma in 
rats as a model, and found to be comparable to that of Dexamethasone. Based on this study, 
Hasan et al. has concluded that chalcones with their pronounced anti-inflammatory activity 
can synergize the activity of Diclofenac when both are in the same compound (codrug).
[41]
 
The classical prodrug approach requires the involvement of an enzyme for the 
interconversion of a prodrug to its active parent drug. On the other hand, enzyme catalysis 
has many disadvantages as a result of many intrinsic and extrinsic factors that can affect the 
interconversion rate. For example, prodrug-activating enzymes activities are largely varied 
due to genetic polymorphisms, age-related physiological changes, or drug interactions, 
resulting in flocculation in drugs’ clinical profiles. Hence, it is necessary to make prodrugs 
having the potential to intraconvert to their active parent drugs through an intramolecular 
process in the absence of enzyme catalysis.
[42-44]
 
 
In the past 6 years we have been studying the mechanisms of a number of intramolecular 
processes which were advocated by others aiming to find chemical devices, mimicking 
enzymes, which could shed light on how enzyme catalyze biotransformations.  On our side 
we have exploited these enzyme models in a novel prodrug chemical approach by which the 
linker (enzyme model) is attached to an active moiety (parent drug) such that the active 
drug’s release rate from the prodrug moiety will be solely dependent on the structural features 
of the linker.  
 
Using molecular quantum and molecular mechanics methods we have designed several 
prodrugs for commonly used drugs suffering from low bioavailability, low water solubility, 
bitter sensation and/or other drawbacks.
[45-99]
 
 
For instance, exploring the mechanism of Kirby’s acetals using DFT methods revealed to the 
design and synthesis of novel prodrugs that intraconvert to their parent drugs in the absence 
of enzymes. Among those are prodrugs of the anti-myelodysplastic aza-nucleosides,
[89]
 anti-
malarial atovaquone,
[90-92]
 anti-cholesterol agents, statins
[93]
 and the decongestant, 
phenylephrine.
[94]
 In these cases, the hydroxyl group of the active parent drug was covalently 
linked to Kirby’s enzyme model (linker) such that the drug-promoiety (prodrug) has the 
potential to undergo cleavage upon exposure to physiological environments such as stomach, 
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intestine, and/or blood circulation, with rates that are solely determined by the structural 
features of the pharmacologically inactive linker (Kirby’s enzyme model).[55-59, 65]  
 
Moreover, prodrugs aiming to eliminate the bitterness of the pain killer paracetamol, the anti-
hypertensive atenolol and the antibiotics, cefuroxime, amoxicillin and cephalexin were 
designed and synthesized.
[45-50]
 The role of the linker in these prodrugs is to block the free 
hydroxyl or amine group, which is believed to be responsible for the drug’s bitter 
sensation.
[84-86, 96-97]
 Prodrugs of the anti-Parkinson disease, dopamine, were designed and 
synthesized via linking the active parent drug with Menger’s Kemp acid enzyme model.[87] 
Similarly, dimethyl fumarate prodrugs were designed and made for the treatment psoriasis.
[88]
        
 
Exploring the mechanism of Kirby’s N-alkylmaleamic acids (enzyme model) has led to the 
design and synthesis of a respected number of prodrugs of the following commonly used 
drugs: the anti-bleeding agent, tranexamic acid,
[82]
 the anti-viral acyclovir,
[83]
 the anti-
hypertensive agent, atenolol.
[84-85]
  
 
Continuing our investigations on how to use the enzyme models that their mechanisms were 
computationally unraveled we have utilized the acid-catalyzed hydrolysis of N-alkyl 
maleamic acids (Kirby’s enzyme model)[59] to design and synthesize codrugs and prodrugs of 
Diclofenac and Tranexamic acid. Our goal was to provide drugs and codrugs of Diclofenac 
with relatively good anti-inflammatory and analgesic activities but with less gastrointestinal 
adverse effects. Additionally, codrugs containing tranexamic acid in which the amine group 
of this acid is replaced with an amide, has the potential to be more permeable and hence more 
bioavailable than Tranexamic acid.  
 
Prodrug and codrugs of Diclofenac were synthesized by the reaction of the acyl chloride of 
Diclofenac with either Tranexamic acid (Figure 11) or benzylamine (Figure 12). Kinetic 
studies on both compounds were carried out at different p s and at 3   C, and monitored by 
HPLC. The kinetic results for the codrug and prodrug are listed in Tables 1 and 2, 
respectively.  
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Figure 11: Schematic diagram for the synthesis of Diclofenac-Tranexamic acid codrug. 
 
 
Figure 12: Schematic diagram for the synthesis of Diclofenac-benzyl amide prodrug. 
 
Table 1: Kinetics parameters for the hydrolysis of diclofenac-tranexamic acid codrug 
Medium t½ (h) 
1N HCl 32.4 
Buffer pH 2.5 No reaction 
Buffer pH 5.5 No reaction 
Buffer pH 7.4 No reaction 
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Table 2: Kinetics parameters for the hydrolysis of diclofenac-benzyl amide prodrug. 
Medium t½ (h) 
1N HCl 10 
Buffer pH 2.5 No reaction 
Buffer pH 5.5 No reaction 
Buffer pH 7.4 11 
 
SUMMARY AND CONCLUSIONS 
This mini review contains most of diclofenac prodrugs and codrugs prepared in the past 
twenty years and a comprehensive description of the different approaches to decrease 
diclofenac gastrointestinal side effects. 
 
Most of the reported prodrugs and codrugs have shown to undergo biotransformation by 
enzymatic catalysis. The latter has many disadvantages because prodrug-activating enzymes 
can vary from person to person due to age or drug and food interaction, which can cause 
variation in clinical effects. Therefore, it is necessary to make prodrugs that have the ability 
to undergo inter- or intraconversion to their parent drugs without the involvement of 
metabolic enzymes such as esterases and amidases.  
 
The computational approach, which has been recently utilized by Karaman’s group, considers 
linking a nontoxic linker to an active drug, such as NSAIDs, that has poor bioavailability or 
suffers from gastrointestinal adverse effects. In Karaman’s approach, the prodrug undergoes 
an intramolecular cleavage to furnish the active parent drug without the need to enzyme 
catalysis. Different linkers can be attached to the drug and the rate of the active drug’s release 
can be determined upon the structural features of the linker attached to the drug.  By this 
approach, the release of the parent drug from its prodrug can be controlled and the variation 
of clinical effects that might be caused by the enzyme catalysis will be prevented. 
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